{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:57:36Z","timestamp":1792519056849,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anemia of chronic kidney disease (CKD) is, in part, caused by hepcidin-mediated impaired iron absorption. However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD\/ESRD patients. The mechanism and sites of intestinal absorption of iron contained in FC were explored here.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eight-week old rats were randomized to sham-operated or 5\/6 nephrectomized (CKD) groups and fed either regular rat chow or rat chow containing 4% FC for 6 weeks. They were then euthanized, and tissues were processed for histological and biochemical analysis using Prussian blue staining, Western blot analysis to quantify intestinal epithelial tight junction proteins and real-time PCR to measure Fatty Acid receptors 2 (FFA2) and 3 (FFA3) expressions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CKD rats exhibited hypertension, anemia, azotemia, and hyperphosphatemia. FC-treated CKD rats showed significant reductions in blood pressure, serum urea, phosphate and creatinine levels and higher serum iron and blood hemoglobin levels. This was associated with marked increase in iron content of the epithelial and subepithelial wall of the descending colon and modest iron deposits in the proximal tubular epithelial cells of their remnant kidneys. No significant difference was found in hepatic tissue iron content between untreated and FC-treated CKD or control groups. Distal colon\u2019s epithelial tight Junction proteins, Occludin, JAM-1 and ZO-1 were markedly reduced in the CKD groups. The FFA2 expression in the jejunum and FFA3 expression in the distal colon were significantly reduced in the CKD rats and markedly increased with FC administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Iron contained in the phosphate binder, FC, is absorbed by the distal colon of the CKD animals via disrupted colonic epithelial barrier and upregulation of short chain fatty acid transporters.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa053","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T20:18:41Z","timestamp":1582921121000},"page":"1136-1144","source":"Crossref","is-referenced-by-count":6,"title":["Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate"],"prefix":"10.1093","volume":"35","author":[{"given":"Nosratola D","family":"Vaziri","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane C F","family":"Nunes","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyder","family":"Said","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Khazaeli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanghui","family":"Jing","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"},{"name":"School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Cogburn","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Alikhani","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-1073","authenticated-orcid":false,"given":"Wei Ling","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"2020081014164416400_gfaa053-B1","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.05","article-title":"SO037 anemia prevalence and treatment among patients with chronic kidney disease outcomes and practice patterns study (CKDOPPS)","volume":"31 (Suppl 1","author":"Wong","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020081014164416400_gfaa053-B2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/prca.201500127","article-title":"Red blood cell abnormalities and the pathogenesis of anemia in end-stage renal disease","volume":"10","author":"Georgatzakou","year":"2016","journal-title":"Prot Clin Appl"},{"key":"2020081014164416400_gfaa053-B3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tracli.2017.06.015","article-title":"Iron metabolism: state of the art","volume":"24","author":"Daher","year":"2017","journal-title":"Transfus Clin Biol"},{"key":"2020081014164416400_gfaa053-B4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0889-8553(05)70036-4","article-title":"Gastrointestinal complications of renal failure","volume":"27","author":"Etemad","year":"1998","journal-title":"Gastroenterol Clin North Am"},{"key":"2020081014164416400_gfaa053-B5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"2020081014164416400_gfaa053-B6","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00467-016-3527-x","article-title":"The gut\u2013kidney axis","volume":"32","author":"Evenepoel","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2020081014164416400_gfaa053-B7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/j.ajkd.2012.10.027","article-title":"Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis","volume":"61","author":"Vaziri","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2020081014164416400_gfaa053-B8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000334939","article-title":"Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion\/infiltration","volume":"35","author":"Kamanna","year":"2012","journal-title":"Am J Nephrol"},{"key":"2020081014164416400_gfaa053-B9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000339285","article-title":"Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes","volume":"36","author":"Ichii","year":"2012","journal-title":"Am J Nephrol"},{"key":"2020081014164416400_gfaa053-B10","first-page":"64","article-title":"At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death","volume":"6","author":"Masuda","year":"2013","journal-title":"Am J Transl Res"},{"key":"2020081014164416400_gfaa053-B11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1681\/ASN.2014090922","article-title":"Considerations and challenges in defining optimal iron utilization in hemodialysis","volume":"26","author":"Charytan","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020081014164416400_gfaa053-B12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10534-011-9409-6","article-title":"Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose","volume":"24","author":"Pai","year":"2011","journal-title":"BioMetals"},{"key":"2020081014164416400_gfaa053-B13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1681\/ASN.2007101084","article-title":"Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients","volume":"19","author":"Kuo","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2020081014164416400_gfaa053-B14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1440-1797.2009.01174.x","article-title":"Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis","volume":"15","author":"Garcia-Fernandez","year":"2010","journal-title":"Nephrology"},{"key":"2020081014164416400_gfaa053-B15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1046\/j.1523-1755.2001.00976.x","article-title":"Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis","volume":"60","author":"Salahudeen","year":"2001","journal-title":"Kidney Int"},{"key":"2020081014164416400_gfaa053-B16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/ajkd.2002.36334","article-title":"Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation","volume":"40","author":"Tovbin","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2020081014164416400_gfaa053-B17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1592\/phco.27.3.343","article-title":"Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2020081014164416400_gfaa053-B18","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1111\/hdi.12557","article-title":"Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: a plea for caution: iron in HCV dialysis patients","volume":"21","author":"Rostoker","year":"2017","journal-title":"Hemodial Int"},{"key":"2020081014164416400_gfaa053-B19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.13020","article-title":"Iron and the liver","volume":"36","author":"Pietrangelo","year":"2016","journal-title":"Liver Int"},{"key":"2020081014164416400_gfaa053-B20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2020081014164416400_gfaa053-B21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020081014164416400_gfaa053-B22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1248\/bpb.b15-01021","article-title":"Effect of a ferric citrate formulation, a phosphate binder, on oxidative stress in chronic kidney diseases-mineral and bone disorder patients receiving hemodialysis: a pilot study","volume":"39","author":"Tanaka","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"2020081014164416400_gfaa053-B23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2020081014164416400_gfaa053-B24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.118.249961","article-title":"Phosphate binder, ferric citrate, attenuates anemia, renal dysfunction, oxidative stress, inflammation, and fibrosis in 5\/6 nephrectomized CKD rats","volume":"367","author":"Jing","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2020081014164416400_gfaa053-B25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.107.123638","article-title":"Intra-renal angiotensin II\/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction","volume":"323","author":"Vaziri","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"2020081014164416400_gfaa053-B26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3109\/0886022X.2014.930491","article-title":"The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats","volume":"36","author":"Matsuo","year":"2014","journal-title":"Ren Fail"},{"key":"2020081014164416400_gfaa053-B27","doi-asserted-by":"crossref","first-page":"F662","DOI":"10.1152\/ajprenal.00421.2009","article-title":"Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure","volume":"298","author":"Kim","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020081014164416400_gfaa053-B28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/gfr560","article-title":"Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease","volume":"27","author":"Aminzadeh","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020081014164416400_gfaa053-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345969","article-title":"Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease","volume":"37","author":"Vaziri","year":"2013","journal-title":"Am J Nephrol"},{"key":"2020081014164416400_gfaa053-B30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000343886","article-title":"Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium","volume":"36","author":"Vaziri","year":"2012","journal-title":"Am J Nephrol"},{"key":"2020081014164416400_gfaa053-B31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MNH.0b013e328358c8d5","article-title":"CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity","volume":"21","author":"Vaziri","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020081014164416400_gfaa053-B32","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2020081014164416400_gfaa053-B33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004836-200603000-00015","article-title":"Colonic health: fermentation and short chain fatty acids","volume":"40","author":"Wong","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"2020081014164416400_gfaa053-B34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000353764","article-title":"Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction","volume":"38","author":"Vaziri","year":"2013","journal-title":"Am J Nephrol"},{"key":"2020081014164416400_gfaa053-B35","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/ndt\/gfr624","article-title":"Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation","volume":"27","author":"Vaziri","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020081014164416400_gfaa053-B36","first-page":"3, doi: 10.3389\/Fendo 2012,00111","article-title":"Short-chain free fatty acid receptors FFA2\/GPR43 and FFA3\/GPR41 as new potential therapeutic targets","author":"Ulven","year":"2012","journal-title":"Front Endocrinol [Internet]"},{"key":"2020081014164416400_gfaa053-B37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fphar.2018.00533","article-title":"The anti-inflammatory effects of short chain fatty acids on lipopolysaccharide- or tumor necrosis factor \u03b1-stimulated endothelial cells via activation of GPR41\/43 and inhibition of HDACs","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2020081014164416400_gfaa053-B38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5483\/BMBRep.2014.47.3.272","article-title":"Perspectives on the therapeutic potential of short-chain fatty acid receptors","volume":"47","author":"Kim","year":"2014","journal-title":"BMB Rep"},{"key":"2020081014164416400_gfaa053-B39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MOG.0000000000000211","article-title":"Gastroduodenal mucosal defense mechanisms","volume":"31","author":"Said","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"2020081014164416400_gfaa053-B40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.118.251389","article-title":"The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease","volume":"367","author":"Lau","year":"2018","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/7\/1136\/33636411\/gfaa053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/7\/1136\/33636411\/gfaa053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T19:31:15Z","timestamp":1597087875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/7\/1136\/5854834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,8]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa053","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,8]]}}}